alexa Oral Mucositis related to Radiotherapy for Head and Neck cancer: Evaluation of the Effectiveness of a New Anti-inflammatory Product Containing Verbascoside, Polyvinylpyrrolidone, Hyaluronic Acid (Mucosyte)
ISSN : 2153-2435

Pharmaceutica Analytica Acta
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

Oral Mucositis related to Radiotherapy for Head and Neck cancer: Evaluation of the Effectiveness of a New Anti-inflammatory Product Containing Verbascoside, Polyvinylpyrrolidone, Hyaluronic Acid (Mucosyte)

Rossella Di Franco1, Matteo Muto3, Vincenzo Ravo2, Domenico Borrelli3, Alfonsina Pepe3, Sara Falivene1*, Angela Argenone2, Giovanna Guida2 and Paolo Muto2

1Radiation Oncology, Second University of Naples, Naples, Italy

2Radiation Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori-Fondazione “Giovanni Pascale” IRCCS, Naples, Italy

3 Radiation Oncology Emicenter, Casavatore, Naples, Italy

*Corresponding Author:
Sara Falivene
Radiation Oncology
Second University of Naples
Pza Miraglia, 80131 Napoli, Italy
Tel: 081 5903277
Fax: 081 5903809
E-mail:[email protected]

Received Date: June 05, 2014; Accepted Date: September 27, 2014; Published Date: September 30, 2014

Citation: Di Franco R, Muto M, Ravo V, Borrelli D, Pepe A, et al. (2014) Oral Mucositis related to Radiotherapy for Head and Neck cancer: Evaluation of the Effectiveness of a New Anti-inflammatory Product Containing Verbascoside, Polyvinylpyrrolidone, Hyaluronic Acid (Mucosyte®). Pharm Anal Acta 5:312. doi: 10.4172/2153-2435.1000312

Copyright: © 2014 Di Franco R, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

 

Abstract

Introduction: Mucositis is a greater complication of chemotherapy and radiotherapy in head and neck cancer,
linked with risk of interruption of therapy. Toxicity is related to reactive oxygen species, which cause transcription
ofNF-kB, iNOS, AP-1, pro-inflammatory cytokines.
Objectives: We have conducted a retrospective study to evaluate the preventive effect of Verbascoside
(Mucosyte®) in the onset of mucositis due to radiotherapy.
Methods: We evaluated 172 patients treated with radiotherapy, divided in two arms: Control Group of 83 patients
treated with 3DCRT or IMRT and with Verbascoside (Mucosyte®) prescribed at appearance of mucositis, and on
the other hand Mucosyte Group of 89 patients treated with 3DCRT, IMRT, Tomotherapy who received Mucosyte®
previously and until two weeks from the end of radiotherapy. Radiotherapy doses were between 30-71.3Gy delivered
with multiple coplanar fields. We calculated the percentage of patients with mucositis grade 1, 2, 3 or 4 in the two
groups of patients, absolute risk reduction (ARR), relative risk (RR), relative risk reduction (RRR) and odds ratio
(OR). We evaluated acute toxicity and Mean Dose (Dmean) to parotid glands to determine techniques’ influence to
onset of mucositis.
Results:The percentage of high toxicity is lower in Mucosyte Group. We calculated: risk of adverse events in MG
PM= 0.17; Odds = 0.20; risk of adverse events in CG Pc = 0.52; Odds = 1.08; Odds Ratio OR = 0.19; relative risk RR:
0.33; relative risk reduction RRR: 0.67; absolute risk reduction ARR: 0.35. All parameters showed the effectiveness
of Verbascoside in management of patients with head and neck cancer.
Conclusions: Using Mucosyte® previously and until two weeks from the end of radiotherapy the incidence of
muscositis is lower but this result is influenced also by technique. Xerostomia, mycosis and pain are much lower in
the patient that used Mucosyte® in prevention independently from technique used.

Share This Page

Additional Info

Loading
Loading Please wait..
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

[email protected]

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

[email protected]

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001 Extn: 9042

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords